GlassScriptPhysician profile
Keith J Derickson
NPI 1538480439
$14,092.01
in general payments reported to CMS, 2019-2025
58 companies · $3,240 in 2025
The $3,240 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $270 · 2021: $1,312 · 2022: $2,907 · 2023: $2,378 · 2024: $2,776 · 2025: $3,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,368 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,367.83 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,202.71 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,336.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,293.63 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,025.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $713.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $606.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $554.94 | 2021-2025 | |
| Tris Pharma INC | $441.86 | 2019-2025 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.93 | 2021-2025 | Jardiance, Stiolto Respimat |
| Sumitomo Pharma America, INC. | $353.96 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $353.77 | 2024-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $300.31 | 2019-2023 | |
| Amgen INC. | $298.69 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $266.90 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.80 | 2020-2025 | Xifaxan |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Derickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.